Multinationals Increase Presence

Two developments have highlighted the attractiveness of China to the pharmaceutical industry. AstraZeneca has revealed that it is to move a significant proportion of raw material production to the Asian country, while contract research organisation (CRO) PPD has acquired Beijing-based BioDuro.

To read the full article, please choose one of the following options: